Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome

Abstract

Three hundred patients with symptomatic, locally advanced or metastatic NSCLC not requiring immediate radiotherapy were enrolled into this randomized multicentre trial comparing gemcitabine + BSC vs BSC alone. Patients allocated gemcitabine received 1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle, for a maximum of six cycles. The main aim of this trial was to compare patient assessment of a predefined subset of commonly reported symptoms (SS14) from the EORTC QLQ-C30 and LC13 scales. The primary end-points were defined as (1) the percentage change in mean SS14 score between baseline and 2 months and (2) the proportion of patients with a marked (> or = 25%) improvement in SS14 score between baseline and 2 months sustained for > or =4 weeks. The secondary objectives were to compare treatments with respect to overall survival, and multidimensional QL parameters. The treatment groups were balanced with regard to age, gender, Karnofsky performance status (KPS) and disease stage (40% had metastatic disease). The percentage change in mean SS14 score from baseline to 2 months was a 10% decrease (i.e. improvement) for gemcitabine plus BSC and a 1% increase (i.e. deterioration) for BSC alone (P = 0.113, two-sample t-test). A sustained (> or = 4 weeks) improvement (> or =25%) on SS14 was recorded in a significantly higher proportion of gemcitabine + BSC patients (22%) than in BSC alone patients (9%) (P = 0.0014, Pearson's chi-squared test). The QLQ-C30 and L13 subscales showed greater improvement in the gemcitabine plus BSC arm (in 11 domains) than in the BSC arm (one symptom item). There was greater deterioration in the BSC alone arm (six domains/items) than in the gemcitabine + BSC arm (three QL domains). Tumour response occurred in 19% (95% CI 13-27) of gemcitabine patients. There was no difference in overall survival: median 5.7 months (95% CI 4.6-7.6) for gemcitabine + BSC patients and 5.9 months (95% CI 5.0-7.9) (log-rank, P = 0.84) for BSC patients, and 1 -year survival was 25% for gemcitabine + BSC and 22% for BSC. Overall, 74 (49%) gemcitabine + BSC patients and 119 (79%) BSC patients received palliative radiotherapy. The median time to radiotherapy was 29 weeks for gemcitabine + BSC patients and 3.8 weeks for BSC. Patients treated with gemcitabine + BSC reported better QL and reduced disease-related symptoms compared with those receiving BSC alone. These improvements in patient-assessed QL were significant in magnitude and were sustained.

References 19

1. 1.

   Aapro M. S., Martin C., Hatty S. Gemcitabine--a safety review. Anticancer Drugs. 1998;9(3):191-201.

   Not in our library10.1097/00001813-199803000-00001

2. 2.

   Aaronson N. K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N. J., Filiberti A., Flechtner H., Fleishman S. B., de Haes J. C. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376.

   Not in our library10.1093/jnci/85.5.365

3. 3.

   Batel-Copel L. M., Kornblith A. B., Batel P. C., Holland J. C. Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Eur J Cancer. 1997;33(1):29-32.

   Not in our library10.1016/s0959-8049(96)00414-5

4. 4.

   Bergman B., Aaronson N. K., Ahmedzai S., Kaasa S., Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30A(5):635-642.

   Not in our library10.1016/0959-8049(94)90535-5

5. 5.

   Brinkley D. Quality of life in cancer trials. Br Med J (Clin Res Ed). 1985;291(6497):685-686.

   Not in our library10.1136/bmj.291.6497.685

6. 6.

   Cox J. D., Stetz J., Pajak T. F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-1346.

   Not in our library10.1016/0360-3016(95)00060-c

7. 7.

   Fernandez C., Rosell R., Abad-Esteve A., Monras P., Moreno I., Serichol M., Roviralta M. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol. 1989;28(1):29-33.

   Not in our library10.3109/02841868909111177

8. 8.

   Hardy J. R., Noble T., Smith I. E. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer. 1989;60(5):764-766.

   Not in our library10.1038/bjc.1989.355

9. 9.

   Hopwood P., Harvey A., Davies J., Stephens R. J., Girling D. J., Gibson D., Parmar M. K. Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee. Eur J Cancer. 1998;34(1):49-57.

   Not in our library10.1016/s0959-8049(97)00347-x

10. 10.

    Hopwood P. Quality of life assessment in chemotherapy trials for non-small cell lung cancer: are theory and practice significantly different? Semin Oncol. 1996;23(5 Suppl 10):60-64.

    Not in our library

11. 11.

    Hopwood P., Stephens R. J., Machin D. Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trial. Qual Life Res. 1994;3(5):339-352.

    Not in our library10.1007/bf00451726

12. 12.
    Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment · 1995

    No notice
13. 13.

    Noble S., Goa K. L. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997;54(3):447-472.

    Not in our library10.2165/00003495-199754030-00009

14. 14.

    Pocock S. J., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103-115.

    Not in our library

15. 15.

    Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1996;73(3):406-413.

    Not in our library10.1038/bjc.1996.71

16. 16.

    Stephens R. J., Hopwood P., Girling D. J. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer. 1999;79(3-4):538-544.

    Not in our library10.1038/sj.bjc.6690085

17. 17.

    Stephens R. J., Hopwood P., Girling D. J., Machin D. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res. 1997;6(3):225-236.

    Not in our library10.1023/a:1026458604826

18. 18.

    Thatcher N., Anderson H., Betticher D. C., Ranson M. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anticancer Drugs. 1995;6(Suppl 6):39-48.

    Not in our library10.1097/00001813-199512006-00007

19. 19.

    Thatcher N., Hopwood P., Anderson H. Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Eur J Cancer. 1997;33(Suppl 1):S8-13.

    Not in our library10.1016/s0959-8049(96)00336-x

Cited by papers we hold 2

• The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV · 2019
  No notice
• Age is a prognostic factor affecting survival in lung cancer patients · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.